US 10399962
Azolopyrimidine for the treatment of cancer-related disorders
granted A61KA61K31/506A61K31/5377
Quick answer
US patent 10399962 (Azolopyrimidine for the treatment of cancer-related disorders) held by Arcus Biosciences, Inc. expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Arcus Biosciences, Inc.
- Grant date
- Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 25
- CPC classes
- A61K, A61K31/506, A61K31/5377, A61K45/06, A61P